Previous 10 | Next 10 |
This article is part of a series that provides an ongoing analysis of the changes made to George Soros's 13F stock portfolio on a quarterly basis. It is based on George Soros's regulatory 13F Form filed on 02/14/2020. Please visit our Tracking Soros Fund Management Holdings article for an ...
The Food and Drug Administration approved three drugs on Friday to switch from prescription status to being available over the counter: GlaxoSmithKline 's (NYSE: GSK) Voltaren Arthritis Pain and two related allergy drugs from Alcon (NYSE: ALC) . The switch, which is typically initiated by...
Now available in the U.S., Pataday® Once Daily Relief is the first and only eye drop to provide all day allergy itch relief without a prescription 1,2 Approximately 66 million Americans who suffer from eye allergies will now have OTC access to long-lasting, prescription-streng...
Under a process called prescription (Rx)-to-OTC switch, the FDA has approved three prescription drugs for non-prescription use. More news on: GlaxoSmithKline plc, Alcon, Inc., Healthcare stocks news, Consumer stocks news, Read more ...
Original post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...
This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers’ 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers’ regulatory 13F Form filed on 01/27/2020. Please visit our Tracking Kahn Brothers Portfolio series t...
Introduction The purpose of this article is to review my investing progress in 2019, which was my eighth full year as a dividend growth investor. I follow a value-oriented dividend growth investing strategy that involves buying attractively valued stocks of companies that consistently pay an...
The following slide deck was published by Alcon, Inc. in conjunction with this Read more ...
Source The Cooper Companies ( COO ) has remained off the radar of many investors despite being a steady growth machine. The company operates in primarily two divisions, surgical and vision, which offer a prestigious brand of products relied upon by professionals every day. The company cont...
Since eye care provider Alcon ( ALC ) was spun off from Novartis ( NVS ) in April, the case for ALC stock has centered on the company's multi-year transformation effort. Alcon struggled as part of Novartis, who bought the company at a $52 billion valuation back in 2011. Revenue, per Novartis...
News, Short Squeeze, Breakout and More Instantly...
2024-07-29 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...